NCT01348828已完成不适用
Prospective, Multicenter, Single Arm Feasibility and Safety Study of the Endologix Fenestrated Stent Graft System for the Endovascular Repair of Juxtarenal/Pararenal (JAA/PAA) Aneurysms
Endologix15 个研究点 分布在 6 个国家目标入组 49 人开始时间: 2011年10月19日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 49
- 试验地点
- 15
- 主要终点
- Primary Safety Endpoint
研究概览
简要总结
The aim of this study is to evaluate the safety and feasibility of the Endologix Fenestrated Stent Graft System for the endovascular repair of juxtarenal or pararenal aortic aneurysms.
详细描述
The Endologix Fenestrated Stent Graft System that will be used in this study has three components, listed below:
- Endologix unibody bifurcated stent graft
- Endologix fenestrated proximal extension stent graft
- Endologix renal stent graft
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adequate iliac/femoral access compatible with the required delivery systems
- •Non-aneurysmal infrarenal aortic neck <15mm in length
- •Most caudal renal artery to aortoiliac bifurcation length >= 70
- •SMA to aortoiliac bifurcation length >=90mm
- •Proximal non-aneurysmal aortic neck below the SMA with diameter 18 to 34 mm, length >=15mm and angle <=60° to the aneurysm sac
- •Angle <=60° (clock face) between the SMA and CA
- •Renal arteries both at or below the SMA by <=35mm and within 30mm of each other axially, with 4 to 8mm lumen diameter, and with clockface angle of 90° to 210° to each other
- •Common iliac artery distal fixation site with: distal fixation length >=15mm, with diameter >=10 mm and <=23 mm and angle <=90° to the aortic bifurcation
- •Ability to preserve at least one hypogastric artery
排除标准
- •Life expectancy <2 years as judged by the investigator
- •Psychiatric or other condition that may interfere with the study
- •Participating in the enrollment or 30-day follow-up phase of another clinical study
- •Known allergy to any device component
- •Coagulopathy or uncontrolled bleeding disorder
- •Contraindication to contrast media or anticoagulants
- •Ruptured, leaking, or mycotic aneurysm
- •Aortic dissection Serum creatinine (S-Cr) level >2.0 mg/dL
- •Traumatic vascular injury
- •Active systemic or localized groin infection
- •Connective tissue disease (e.g., Marfan's Syndrome)
- •Recent(within prior three months)cerebrovascular accident
- •Recent(within prior three months)myocardial infarction
- •Prior renal transplant
- •Length of either renal artery to be stented <12mm
- •Significant occlusive disease or calcification of either renal artery (>70%)
- •An essential accessory renal artery
- •Indispensable inferior mesenteric artery
- •Untreated aneurysmal disease of the descending thoracic aorta
- •Clinically significant mural thrombus circumferentially in the suprarenal segment
- •Prior iliac artery stent implanted that may interfere with delivery system introduction
- •Unsuitable vascular anatomy
- •Pregnancy
结局指标
主要结局
Primary Safety Endpoint
时间窗: 30 days
Major adverse events defined as: * All-cause death * Bowel ischemia * Myocardial infarction * Paraplegia * Renal failure * Respiratory failure * Stroke * Blood loss \>=1,000cc
次要结局
- Mortality(Procedurally and to 5 Years)
- Feasibility/Effectiveness(1 Year)
- Stent Graft Patency(30 Days, 6 Months, and Years 1 to 5)
- Major Adverse Events(>30 Days to 5 Years)
- Number of Participants With Renal Dysfunction(30 Days, 6 Months and Years 1 to 5)
- Aneurysm Rupture(Procedurally and to 5 Years)
- Device Integrity(30 Days, 6 Months, and Years 1 to 5)
- Aneurysm Diameter Change(6 Months, and Years 1 to 5)
- Procedural/In-hospital Evaluations(Discharge)
- Secondary Procedures(30 Days, 6 Month and Years 1 to 5)
- Conversion to Open Repair(Procedurally and to 5 Years)
研究者
研究点 (15)
Loading locations...
相似试验
已完成
不适用
Pilot Study of the Endologix Fenestrated Stent Graft SystemJuxtarenal Aortic AneurysmPararenal Aortic AneurysmNCT01437215Endologix15
已完成
不适用
Safety and Effectiveness Trial of the Ventana Fenestrated Stent Graft SystemAbdominal Aortic AneurysmNCT01491945Endologix76
已完成
3 期
Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)Coronary DiseaseNCT00165035Cordis Corporation1,701
已完成
不适用
Efficacy and Safety of GENOSS® DES in Patients with Coronary Artery DiseaseCoronary Artery DiseaseNCT06066476Genoss Co., Ltd.1,022
招募中
不适用
To Evaluate the Safety and Efficacy of Intracranial Stent Assisted Endovascular Treatment of Intracranial AneurysmsIntracranial AneurysmNCT06158087Shanghai Wallaby Medical Technologies Co.,Inc.130